The favorable outlook for the pharmaceutical industry has triggered a wave of mergers and acquisitions (M&A) in the country, with the amount and number of M&A repeatedly hitting record highs. Due to optimistic about the development of the domestic pharmaceutical industry, Chinese enterprises in the overseas market mergers and acquisitions of the same enthusiasm.
According to the incomplete statistics of the "China Pharmaceutical Industry In-depth Research and Investment Strategy Planning Analysis Report" released, in 2016, there were more than 400 mergers and acquisitions in the field of medicine and health, amounting to more than 180 billion yuan. It is expected that the wave of mergers and acquisitions will continue this year, and mergers and acquisitions in various segments will remain highly active.
According to the current trend, mergers and acquisitions in the pharmaceutical industry will continue, and in the future, until the new market pattern is basically formed, pharmaceutical mergers and acquisitions will be relatively slowed down. After the formation of the new pattern, the pharmaceutical industry will also return to the medium and high speed development.
Overall, with the aging of society, the deepening of the reform of the separation of medicine, as well as the untying of the policy of pharmaceutical e-commerce, the outlook for the pharmaceutical industry is still promising. In the new market environment, pharmaceutical companies to seek new sales channels, increase the integration of efforts with the Internet, to reduce the cost of circulation, increase their profits.